AI Investment Championship

Cloud saving enabled

Cloud saving enabled. Updates are stored securely and available across your devices.

Season 2026Jul 26, 2026Jul 24, 2027Week 6 of 52active

JNJ Intelligence

Overview, health ratings, scorecard, and competition exposure

JNJ

NYSESeed fundamentals

Johnson & Johnson

Healthcare · Drug Manufacturers — General · United States

$158.00

Mkt cap $380B

Excellent

Overview

Market Cap

$380B

Price

$158.00

52W High

$170.00

52W Low

$140.00

Avg Volume

7M

Dividend Yield

3.1%

Beta

0.55

Analyst Target

$170.00

Business Summary

Diversified healthcare company spanning pharmaceuticals and medtech.

Financial Health

Normalized category ratings with evidence — Unknown when inputs are missing

OverallExcellent

Each category rates only the metrics present for the company. Thresholds are deterministic rules (liquidity ratios, margins, growth rates, leverage, returns, cash flow, beta/short interest). Missing inputs yield Unknown for that category — values are never invented.

Liquidity

Good
  • Current ratio 1.2–2$1.2
  • Net debt present (cash − debt)-$10B

Profitability

Excellent
  • ROE ≥ 25%25.0%
  • Operating margin ≥ 25%25.0%
  • Gross margin ≥ 50%69.0%

Growth

Fair
  • Revenue growth 3–12%4.0%
  • EPS growth 0–10%6.0%

Balance Sheet

Excellent
  • Debt/Equity < 0.545.0%
  • Cash below total debt$0.71

Capital Allocation

Excellent
  • ROIC 12–20%16.0%
  • Positive free cash flow$18B
  • Pays a dividend (allocation signal, not required)3.1%

Efficiency

Excellent
  • ROE ≥ 20%25.0%
  • ROIC ≥ 15%16.0%
  • Operating margin ≥ 20%25.0%

Cash Flow

Excellent
  • Positive free cash flow$18B
  • Operating margin supports cash conversion25.0%

Risk

Excellent
  • Beta < 0.9 (lower market sensitivity)$0.55
  • Short interest < 2%0.6%
  • Low leverage45.0%

Growth

Revenue Growth

4.0%

EPS Growth

6.0%

PEG

2.5x

Valuation

P/E

15.5x

Forward P/E

14.0x

PEG

2.5x

Price/Sales

4.2x

Price/Book

5.0x

Profitability

ROE

25.0%

ROIC

16.0%

Operating Margin

25.0%

Gross Margin

69.0%

Free Cash Flow

$18B

Ownership

Institutional

70.0%

Insider

0.1%

Short Interest

0.6%

Analyst Rating

Hold

Risk

Beta

0.55

Debt/Equity

0.5x

Current Ratio

1.2

Cash

$25B

Debt

$35B

Short Interest

0.6%

Technical Overview

Price

$158.00

52W High

$170.00

52W Low

$140.00

Avg Volume

7M

Chart indicators and pattern detection are reserved for a later sprint.

Investment Scorecard

Transparent category scores — no single magical AI composite

Category scores are transparent and independent. There is no single composite AI score. Missing fundamentals reduce coverage; they do not fabricate a middle score.

Financial Health

All financial health categories had enough evidence to rate.

83Excellent

Average of Liquidity, Profitability, Growth, Balance Sheet, Capital Allocation, Efficiency, Cash Flow, and Risk ratings. Unknown categories are excluded (not filled with a neutral score).

Used: Liquidity, Profitability, Growth, Balance Sheet, Capital Allocation, Efficiency, Cash Flow, Risk

Growth

Scored from revenueGrowth and epsGrowth.

52Fair

Uses revenue growth and EPS growth bands. Higher sustained growth scores higher; negative EPS growth scores Weak.

Used: revenueGrowth, epsGrowth

Valuation

All valuation inputs present.

61Fair

Average of P/E, Forward P/E, PEG, and Price/Sales bands. Lower multiples score higher. This is a mechanical screen, not a fair-value model.

Used: pe, forwardPe, peg, priceToSales

Quality

Based on roe, roic, grossMargin.

90Excellent

Combines ROE, ROIC, and gross margin quality bands.

Used: roe, roic, grossMargin

Risk

Beta, short interest, and leverage all available.

90Excellent

Higher scores mean lower measured risk from beta, short interest, and leverage. Not a volatility forecast.

Used: beta, shortInterest, debtToEquity

Technical

Mechanical range/liquidity score; not investment advice.

69Good

Foundation heuristic only: 52-week range position plus liquidity (average volume). Not a chart pattern or indicator suite — reserved for future Technical Overview expansion.

Used: currentPrice, week52High, week52Low, averageVolume

Momentum

Proxy momentum only; not a returns-based momentum factor.

69Good

Proximity to 52-week high plus EPS growth as a fundamentals momentum proxy. No price time-series yet — extension point for Sprint 19+.

Used: currentPrice, week52High, epsGrowth

Recent News

News feed placeholder

Live news integration will plug into IntelligenceService in a future sprint.

AI Research

AI research placeholder

Consensus and research briefs will reuse Market Terminal research providers without changing that module.

Competition Exposure

AI Investment Championship · Week 5

Open Strategy Lab →

Owned by

0

Competitors

5

Largest owner

Average weight

Current leader owns? No (Perplexity)Backtest ownership: No

Not currently owned

No competitor holds this ticker in the latest week.

Historical ownership

No historical ownership in available weeks.

Most recent trade

No recorded trades for this ticker in the competition.

← Back to stocks